IL6 and myeloid sarcoma: Therefore, to help resolve this controversy concerning the inflammatory (pro- or anti-inflammatory) and endocrine (whether or not inducive of insulin resistance, and therefore hypo-or hyper-glycaemic) effects of IL-6 in MS, it is vital to clarify whether inflammation is the cause or the consequence of metabolic dysregulation.